Diffuse small cleaved-cell lymphoma

A heterogeneous disease with distinct immunobiologic subsets

Catherine P. Leith, Catherine S Perry, Thomas M. Grogan, Guillermo Gonzales, Catherine S. Rangel, James A. Rybski, Monika Matzner, Thomas P Miller

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

Purpose and Methods: Diffuse small cleaved-cell lymphoma (DSCL) is a relatively uncommon non-Hodgkin's lymphoma (NHL) in the United States and has not been the subject of recent in-depth study of factors predictive of outcome. It is unique among the NHL of intermediate grade because there is no evidence of a curable subset of patients. To investigate whether any laboratory data might predict outcome, we studied 33 cases collected during a 12-year period and correlated morphology, immunohistochemistry, and serum lactate dehydrogenase (LDH) with clinical data and outcome. Results: We found that proliferative rate (Ki-67), cell lineage (T v B cell), and serum LDH were associated with significant differences in survival. A Ki-67 value ≥ 20% was associated with a median survival of 20 months compared with 80 months for lower values (P = .0002); patients with tumors of T-cell lineage had a median survival of 20 months compared with 40 months for those with B-cell neoplasms (P = .0143); and a serum LDH greater than 225 IU/L was associated with a median survival of 8 months compared with 40 months for lower LDH levels (P = .0004). Blastoid morphology was also linked to a trend toward poor outcome (P = .08). Neither a history of low-grade lymphoma nor the presence of residual immunologically detectable follicles influenced outcome (P = .93 and .97, respectively). Conclusion: We conclude that high Ki-67, high LDH, and T-cell lineage each identify DSCL patients with poor outcome.

Original languageEnglish (US)
Pages (from-to)1259-1265
Number of pages7
JournalJournal of Clinical Oncology
Volume10
Issue number8
StatePublished - 1992

Fingerprint

L-Lactate Dehydrogenase
Non-Hodgkin's Lymphoma
Cell Lineage
Survival
B-Lymphocytes
Serum
T-Lymphocytes
Neoplasms
Immunohistochemistry

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Diffuse small cleaved-cell lymphoma : A heterogeneous disease with distinct immunobiologic subsets. / Leith, Catherine P.; Perry, Catherine S; Grogan, Thomas M.; Gonzales, Guillermo; Rangel, Catherine S.; Rybski, James A.; Matzner, Monika; Miller, Thomas P.

In: Journal of Clinical Oncology, Vol. 10, No. 8, 1992, p. 1259-1265.

Research output: Contribution to journalArticle

Leith, CP, Perry, CS, Grogan, TM, Gonzales, G, Rangel, CS, Rybski, JA, Matzner, M & Miller, TP 1992, 'Diffuse small cleaved-cell lymphoma: A heterogeneous disease with distinct immunobiologic subsets', Journal of Clinical Oncology, vol. 10, no. 8, pp. 1259-1265.
Leith, Catherine P. ; Perry, Catherine S ; Grogan, Thomas M. ; Gonzales, Guillermo ; Rangel, Catherine S. ; Rybski, James A. ; Matzner, Monika ; Miller, Thomas P. / Diffuse small cleaved-cell lymphoma : A heterogeneous disease with distinct immunobiologic subsets. In: Journal of Clinical Oncology. 1992 ; Vol. 10, No. 8. pp. 1259-1265.
@article{8f11d591cbec44b2b2c9b3dbe9b990ec,
title = "Diffuse small cleaved-cell lymphoma: A heterogeneous disease with distinct immunobiologic subsets",
abstract = "Purpose and Methods: Diffuse small cleaved-cell lymphoma (DSCL) is a relatively uncommon non-Hodgkin's lymphoma (NHL) in the United States and has not been the subject of recent in-depth study of factors predictive of outcome. It is unique among the NHL of intermediate grade because there is no evidence of a curable subset of patients. To investigate whether any laboratory data might predict outcome, we studied 33 cases collected during a 12-year period and correlated morphology, immunohistochemistry, and serum lactate dehydrogenase (LDH) with clinical data and outcome. Results: We found that proliferative rate (Ki-67), cell lineage (T v B cell), and serum LDH were associated with significant differences in survival. A Ki-67 value ≥ 20{\%} was associated with a median survival of 20 months compared with 80 months for lower values (P = .0002); patients with tumors of T-cell lineage had a median survival of 20 months compared with 40 months for those with B-cell neoplasms (P = .0143); and a serum LDH greater than 225 IU/L was associated with a median survival of 8 months compared with 40 months for lower LDH levels (P = .0004). Blastoid morphology was also linked to a trend toward poor outcome (P = .08). Neither a history of low-grade lymphoma nor the presence of residual immunologically detectable follicles influenced outcome (P = .93 and .97, respectively). Conclusion: We conclude that high Ki-67, high LDH, and T-cell lineage each identify DSCL patients with poor outcome.",
author = "Leith, {Catherine P.} and Perry, {Catherine S} and Grogan, {Thomas M.} and Guillermo Gonzales and Rangel, {Catherine S.} and Rybski, {James A.} and Monika Matzner and Miller, {Thomas P}",
year = "1992",
language = "English (US)",
volume = "10",
pages = "1259--1265",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "8",

}

TY - JOUR

T1 - Diffuse small cleaved-cell lymphoma

T2 - A heterogeneous disease with distinct immunobiologic subsets

AU - Leith, Catherine P.

AU - Perry, Catherine S

AU - Grogan, Thomas M.

AU - Gonzales, Guillermo

AU - Rangel, Catherine S.

AU - Rybski, James A.

AU - Matzner, Monika

AU - Miller, Thomas P

PY - 1992

Y1 - 1992

N2 - Purpose and Methods: Diffuse small cleaved-cell lymphoma (DSCL) is a relatively uncommon non-Hodgkin's lymphoma (NHL) in the United States and has not been the subject of recent in-depth study of factors predictive of outcome. It is unique among the NHL of intermediate grade because there is no evidence of a curable subset of patients. To investigate whether any laboratory data might predict outcome, we studied 33 cases collected during a 12-year period and correlated morphology, immunohistochemistry, and serum lactate dehydrogenase (LDH) with clinical data and outcome. Results: We found that proliferative rate (Ki-67), cell lineage (T v B cell), and serum LDH were associated with significant differences in survival. A Ki-67 value ≥ 20% was associated with a median survival of 20 months compared with 80 months for lower values (P = .0002); patients with tumors of T-cell lineage had a median survival of 20 months compared with 40 months for those with B-cell neoplasms (P = .0143); and a serum LDH greater than 225 IU/L was associated with a median survival of 8 months compared with 40 months for lower LDH levels (P = .0004). Blastoid morphology was also linked to a trend toward poor outcome (P = .08). Neither a history of low-grade lymphoma nor the presence of residual immunologically detectable follicles influenced outcome (P = .93 and .97, respectively). Conclusion: We conclude that high Ki-67, high LDH, and T-cell lineage each identify DSCL patients with poor outcome.

AB - Purpose and Methods: Diffuse small cleaved-cell lymphoma (DSCL) is a relatively uncommon non-Hodgkin's lymphoma (NHL) in the United States and has not been the subject of recent in-depth study of factors predictive of outcome. It is unique among the NHL of intermediate grade because there is no evidence of a curable subset of patients. To investigate whether any laboratory data might predict outcome, we studied 33 cases collected during a 12-year period and correlated morphology, immunohistochemistry, and serum lactate dehydrogenase (LDH) with clinical data and outcome. Results: We found that proliferative rate (Ki-67), cell lineage (T v B cell), and serum LDH were associated with significant differences in survival. A Ki-67 value ≥ 20% was associated with a median survival of 20 months compared with 80 months for lower values (P = .0002); patients with tumors of T-cell lineage had a median survival of 20 months compared with 40 months for those with B-cell neoplasms (P = .0143); and a serum LDH greater than 225 IU/L was associated with a median survival of 8 months compared with 40 months for lower LDH levels (P = .0004). Blastoid morphology was also linked to a trend toward poor outcome (P = .08). Neither a history of low-grade lymphoma nor the presence of residual immunologically detectable follicles influenced outcome (P = .93 and .97, respectively). Conclusion: We conclude that high Ki-67, high LDH, and T-cell lineage each identify DSCL patients with poor outcome.

UR - http://www.scopus.com/inward/record.url?scp=0026776290&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026776290&partnerID=8YFLogxK

M3 - Article

VL - 10

SP - 1259

EP - 1265

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 8

ER -